- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00620984
Staphylococcus Aureus Carrier Status in Breastfeeding Mothers and Infants and the Risk of Lactation Mastitis
Staphylococcus Aureus Carrier Status in Breastfeeding Mothers and Infants and the Risk of Lactation Mastitis: A Large Prospective Study
Lactation (breastfeeding) mastitis is an acute infection of the milk ducts of the breastfeeding woman. Staphylococcus aureus (S. aureus) is the infectious germ most commonly associated with lactation mastitis. Twenty percent of the general population are carriers of Staphylococcus aureus, which means that they carry the infectious germ but do not become ill from it. It has been suggested that mothers who are carriers of S. aureus in their nostril may be at an increased risk of developing lactational mastitis, however; this has not been clinical proven.
We are studying the relationship between S. aureus carrier status of breastfeeding mothers and infants and the risk of developing lactational mastitis. Additionally, we are collecting questionnaire data in an attempt to better define factors predisposing women to lactation mastitis.
Study Overview
Status
Detailed Description
Lactation mastitis is an acute inflammation of the interlobular connective tissue within the mammary gland of a breastfeeding woman. It is a relatively common condition that causes pain and worry, and can lead to restriction in activity and increased risk of early weaning from breastfeeding. Staphylococcus aureus is the infectious agent most commonly implicated in lactation mastitis.
It is well established that the anterior nares are the primary reservoir of S. aureus in humans and that approximately 20% of healthy individuals are "persistent carriers" of the organism. Carriage of Staphylococcus aureus has been identified as a significant risk factor for the development of infection including surgical wound infections. It has been suggested that maternal and infant nasal carriage of S. aureus may be associated with an increased risk of breast infection during lactation.
We propose to prospectively study the relationship between the S. aureus carrier status of 500 healthy breastfeeding dyads and the rate of the subsequent development of lactational mastitis. Carrier status of mothers and infants will be determined through two nasal swabbings performed in the early post-partum period. The swabs will be analyzed with both traditional culture and through Polymerase chain reaction (PCR) amplification analysis. Mastitis rate will be determined via serial follow-up telephone interviews during the first two months post-partum.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
New York
-
Syracuse, New York, United States, 13210
- SUNY Upstate Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Mother must plan to breastfeed exclusively for at least two months
- Mother must be 18 years or older.
- Mother must speak English and capable of giving informed consent
- Must be the delivery of a term (37 weeks or more), singleton live infant.
- Mother must be within post-partum day zero to three-status post delivery
- Both mother and infant generally healthy without disease known to cause significant immune dysfunction or known to be associated with abnormally high carriage rates of S. aureus such as HIV-positive status or AIDS, Type I Diabetes Mellitus, ongoing need for hemodialysis or chronic steroid use, or receiving either chemotherapy/radiation treatment for malignancy?
- Must have the ability to communicate via phone for follow up assessments.
Exclusion Criteria:
- Does not have the ability to drop off the second set of cultures.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Our primary objective is to determine the association of nasal carriage of S. aureus in breastfeeding mothers and infants with the rate development of mastitis in the mothers.
Time Frame: Culture results will be unblinded at the end of the study.
|
Culture results will be unblinded at the end of the study.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Secondary objective will be to document the S. aureus carriage rate, including methicillin-resistant Staphylococcus aureus (MRSA), in early post-partum period and to assess the relationship between S. aureus carrier status of the mother and the infant.
Time Frame: Culture results will be unblinded at the end of the study.
|
Culture results will be unblinded at the end of the study.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jayne R Charlamb, MD, IBCLC, State University of New York - Upstate Medical University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 5395
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Staphylococcus Aureus
-
University Hospital TuebingenRecruitingStaphylococcus AureusGermany
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
University of SheffieldRajarata University, Sri LankaUnknown
-
Hospital Universitari de BellvitgeInstitut d'Investigació Biomèdica de Bellvitge; Hospital Universitario Virgen... and other collaboratorsActive, not recruitingStaphylococcal Aureus Infection | Staphylococcus Aureus BacteraemiaSpain
-
NovaDigm Therapeutics, Inc.Uniformed Services University of the Health Sciences; Infectious Diseases Clinical...CompletedStaphylococcus AureusUnited States
-
AstraZenecaParexelNot yet recruitingStaphylococcus Aureus Bloodstream InfectionJapan
-
West Virginia UniversityEnrolling by invitationStaphylococcus Aureus BacteremiaUnited States
-
McGill University Health Centre/Research Institute...University of MelbourneRecruitingStaphylococcus Aureus Bacteremia | Staphylococcus Aureus Endocarditis | Staphylococcus Aureus Septicemia | S. Aureus Bacteremia | S. Aureus Bloodstream Infection | Staphylococcus Aureus Bloodstream InfectionCanada
-
Intermountain Health Care, Inc.Not yet recruitingStaphylococcus Aureus BacteremiaUnited States
-
Todd C. Lee MD MPH FIDSAUniversity of Melbourne; The Peter Doherty Institute for Infection and ImmunityRecruitingStaphylococcus Aureus Bacteremia | Staphylococcus Aureus Endocarditis | Staphylococcus Aureus Septicemia | S. Aureus Bacteremia | S. Aureus Bloodstream InfectionAustralia, Canada